Doxorubicin

Breastfeeding
  • TRADE NAMES: Adiblastine; Adriablastine; Adriacin; Adriamycin (Bedford); Adriblatina; Doxil (Tibotec); Farmablastina; Rubex (Mead Johnson)
  • INDICATIONS: Carcinomas, leukemias, sarcomas
  • SYNONYM: hydroxydaunomycin
  • CLASS: Antibiotic, Antibiotic; anthracycline, Antimicrobial
  • HALF-LIFE: 20–48 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Aldesleukin, Cabazitaxel, CYP2D6 inhibitors or inducers, CYP3A4 inhibitors or inducers, Gadobenate, P-glycoprotein inhibitors or inducers, Paclitaxel, Sorafenib, Stavudine, Trastuzumab, Zidovudine

PREGNANCY CATEGORY: D

CARDIOMYOPATHY, SECONDARY MALIGNANCIES, EXTRAVASATION AND TISSUE NECROSIS, and SEVERE MYELOSUPPRESSION

See full prescribing information for complete boxed warning.

Our database has 148 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
HAIR.
NAILS.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
OTIC.
RENAL.
RESPIRATORY.
OTHER.


Page last updated 02/16/2024

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top